Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT02376010

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02376010
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02376010. Randomized; no masking; primary purpose prevention. Start 2015-04-02 (actual); primary completion 2018-04-01 (actual). Results posted on 2021-07-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Condition
Atherosclerosis
Intervention (Drug)
rivaroxaban
Intervention (Drug)
Warfarin
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (class: other)

Record details

Record id
cardio:ct-nct02376010
Content hash
d9ad9a4829e2e27f1b7764d3001808ac4979f32eeb4e5a213d3b6c5eb981a819